Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Directorate Change

26 Jan 2016 07:00

RNS Number : 9451M
NetScientific PLC
26 January 2016
Β 

NetScientific plc

Β 

Board Change

Β 

London, UKΒ - 26 January 2016 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced the resignation from the board of Peter Thoms, Chief Financial Officer. Peter leaves the company in order to pursue new challenges, particularly in the technology sector. Peter has been with the Group since inception and has been heavily involved in building the current business. His contribution has been significant and much appreciated. The Board wish Peter all the best in his new ventures.

The Board has initiated a process to recruit a new Chief Financial Officer and an announcement will be made in due course. In the meantime Mark Nanovich, the current Group Finance Director, will assume the role of interim Chief Financial Officer. Mark joined the Group in October 2014 and is a chartered accountant.

Β 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website atΒ www.netscientific.net.Β 

Β 

Β - Ends -

Β 

Contact Details

NetScientific

FranΓ§ois R. Martelet, M.D., CEO

Β 

Tel: +44 (0)20 3514 1800

Β 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Β 

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email:Β netscientific@instinctif.com

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAFELLLQFFFBBX
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.